Abstract

Acute ischemic stroke (AIS) is a global cerebrovascular disease with high disability and mortality, which has no effective therapy. Studies have demonstrated that astrocyte-derived exosomes (ADEXs) provided neuroprotection in experimental stroke models. Nevertheless, the role of exosomes derived from oxygen-glucose-deprivation/reoxygenation-stimulated astrocytes (OGD/R-stimulated astrocytes; OGD/R-ADEXs) in AIS remains largely unknown. Here, we found that OGD/R-ADEXs significantly reduced OGD/R-induced neuronal death and promoted neuronal autophagy. These effects were reversed when astrocytes were pretreated with GW4869, an exosome secretion inhibitor, or when hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) was knocked down. Neuroprotection was also observed during treatment with OGD/R-ADEXs in vivo. Further studies showed that Nampt, played a vital effect in the regulation of autophagy, was significantly increased in OGD/R-ADEXs. Knockdown of Nampt in astrocytes abolished the above-mentioned effects of OGD/R-ADEXs. Mechanistically, Nampt increased autophagy and decreased cell death by modulating AMPK/mTOR signaling, which recognized as a key signaling pathway of autophagy after AIS. Collectively, these results showed that Nampt released by OGD/R-ADEXs ameliorated acute ischemic stroke during neuronal injury by targeting AMPK/mTOR signaling to induce autophagy. Our study revealed a new key factor in the secretion of exosomes by OGD/R astrocytes, which regulated autophagy and induced neuroprotection in a mouse stroke model.

Details

Title
Astrocyte-derived exosomal nicotinamide phosphoribosyltransferase (Nampt) ameliorates ischemic stroke injury by targeting AMPK/mTOR signaling to induce autophagy
Author
Deng, Yang 1 ; Duan, Rui 2 ; Ding, Wangli 1 ; Gu, Qiuchen 1 ; Liu, Manman 1 ; Zhou, Junshan 2 ; Sun, Jianguo 3 ; Zhu, Junrong 1   VIAFID ORCID Logo 

 Nanjing Medical University, Department of Pharmacy, Nanjing First Hospital, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); China Pharmaceutical University, School of Basic Medicine & Clinical Pharmacy, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 Nanjing Medical University, Department of Neurology, Nanjing First Hospital, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
 China Pharmaceutical University, Key Lab of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
Pages
1057
Publication year
2022
Publication date
Dec 2022
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2755978329
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.